Trials / Completed
CompletedNCT01379300
A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)
A Randomized Clinical Trial to Validate Novel Biomarker Approaches After Single Doses of Anticoagulants in Healthy Young Male Subjects and in Healthy Elderly Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
This is a study to investigate biomarkers after single oral doses of the anticoagulant agents dabigatran etexilate and rivaroxaban in healthy young male subjects and in healthy elderly subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dabigatran etexilate | dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration |
| DRUG | rivaroxaban | rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2011-06-23
- Last updated
- 2015-10-02
Source: ClinicalTrials.gov record NCT01379300. Inclusion in this directory is not an endorsement.